论文部分内容阅读
目的:比较新辅助CMF方案【环磷酰胺(CTX)+甲氨蝶呤(MTX)+5-氟尿嘧啶(5-FU)】和新辅助TA方案(表阿霉素+紫杉醇)对小于全乳切除术前新辅助化疗的治疗效果。方法:将该院2011年7月~2013年7月收治的乳腺癌女性患者86例随机分为观察组和对照组,观察组采用新辅助TA方案化疗,对照组采用新辅助CMF化疗,观察治疗4个疗程之后两组患者B超下肿块大小、新辅助化疗的总有效率、测定化疗前后两组患者的白细胞、血红蛋白、血小板、谷丙转氨酶(GPT)水平;观察患者化疗后不良反应包括恶心呕吐、脱发、口腔炎的发生情况。结果:两组患者新辅助化疗后的B超下肿块均显著减小,但观察组肿块小于对照组(P<0.01);观察组患者的总有效率显著高于对照组(P<0.01);化疗后观察组的白细胞、血红蛋白和血小板水平显著高于对照组,GPT显著低于对照组(P<0.01);化疗后观察组各种不良反应发生率显著低于对照组(P<0.05)。结论:小于全乳切除术前新辅助TA方案治疗乳腺癌可通过明显缩小病灶获得较好疗效,使更多患者获得保乳机会,且化疗后不良反应较小,值得临床上推广应用。
OBJECTIVE: To compare the effect of neoadjuvant CMF regimen (CTX + MTX + 5-FU) and neoadjuvant TA regimen (epirubicin + paclitaxel) Preoperative neoadjuvant chemotherapy treatment effect. Methods: Eighty-six women with breast cancer admitted to our hospital from July 2011 to July 2013 were randomly divided into observation group and control group. Neoadjuvant TA regimen was used in the observation group and neoadjuvant CMF chemotherapy in the control group. Observation and treatment After 4 courses of treatment, the size of subsidence and the total effective rate of neoadjuvant chemotherapy in both groups were measured. The levels of leukocyte, hemoglobin, platelet and alanine aminotransferase (GPT) in both groups were measured before and after chemotherapy. The adverse reactions after chemotherapy were observed including nausea Vomiting, hair loss, the occurrence of stomatitis. Results: The mass of B ultrasound after neoadjuvant chemotherapy in both groups was significantly decreased, but the mass in the observation group was smaller than that in the control group (P <0.01). The total effective rate in the observation group was significantly higher than that in the control group (P <0.01). The levels of leukocyte, hemoglobin and platelet in the observation group after chemotherapy were significantly higher than those in the control group (P <0.01). The incidence of various adverse reactions in the observation group after chemotherapy was significantly lower than that in the control group (P <0.05). Conclusions: Neoadjuvant TA regimen less than total neoadjuvant TA is effective in reducing the risk of breast cancer. It can make more patients get the chance of breast - conserving and have less side effects after chemotherapy. It is worth popularizing and applying in clinic.